Related references
Note: Only part of the references are listed.Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment
In Hae Park et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
Kazuma Kiyotani et al.
DRUG METABOLISM AND PHARMACOKINETICS (2012)
Distribution of CYP2D6 and CYP2C19 Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico
Joel Salazar-Flores et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS (2012)
CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial
Meredith M. Regan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Pharmacogenetics of Endocrine Therapy for Breast Cancer
Michaela J. Higgins et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes
Madhu S. Singh et al.
BREAST (2011)
Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population
Vanessa Da Silva Silveira et al.
BIOMARKERS (2009)
Genetic Polymorphisms of CYP2D6*10 and CYP2C19*2,*3 Are not Associated With Prognosis, Endometrial Thickness, or Bone Mineral Density in Japanese Breast Cancer Patients Treated With Adjuvant Tamoxifen
Masatsugu Okishiro et al.
CANCER (2009)
No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment
Tatsuya Toyama et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2009)
CYP2D6 and tamoxifen: DNA matters in breast cancer
Janelle M. Hoskins et al.
NATURE REVIEWS CANCER (2009)
The peopling of America:: Craniofacial shape variation on a continental scale and its interpretation from an interdisciplinary view
Rolando Gonzalez-Jose et al.
AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY (2008)
Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy
Kazuma Kiyotani et al.
CANCER SCIENCE (2008)
Statistical evaluation of alternative models of human evolution
Nelson J. R. Fagundes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Beringian Standstill and Spread of Native American Founders
Erika Tamm et al.
PLOS ONE (2007)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients
SA Nowell et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity
M Ingelman-Sundberg
PHARMACOGENOMICS JOURNAL (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
P Wegman et al.
BREAST CANCER RESEARCH (2005)
CYP2D6 variants and the prediction of tamoxifen response in randomized patients: authors' response
PP Wegman et al.
BREAST CANCER RESEARCH (2005)
57 varieties: the human cytochromes P450
DFV Lewis
PHARMACOGENOMICS (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
The African-specific C Upsilon P2D6*17 allele encodes an enzyme with changed substrate specificity
A Wennerholm et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2002)
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
LD Bradford
PHARMACOGENOMICS (2002)
Genotyping of cytochrome P450 2D6*3 and*4 mutations using conventional PCR
BC Schur et al.
CLINICA CHIMICA ACTA (2001)
Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population
CA Isaza et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2000)
Share Paper
